MicroRNA: Potential biomarkers in chronic kidney disease

IF 0.3 Q3 MEDICINE, GENERAL & INTERNAL Acta Facultatis Medicae Naissensis Pub Date : 2023-01-01 DOI:10.5937/afmnai40-39805
Vladana Stojiljković, Nikola Stefanović, Marija Vukelić-Nikolić, Branka Đorđević, Jelena Bašić, Gordana Kocić, Tatjana Cvetković
{"title":"MicroRNA: Potential biomarkers in chronic kidney disease","authors":"Vladana Stojiljković, Nikola Stefanović, Marija Vukelić-Nikolić, Branka Đorđević, Jelena Bašić, Gordana Kocić, Tatjana Cvetković","doi":"10.5937/afmnai40-39805","DOIUrl":null,"url":null,"abstract":"Introduction. Standard biomarkers for the diagnosis and follow-up of chronic kidney disease patients are appropriate neither in early diagnostics, adequate follow-up and progression assessment nor in complication development risk assessment. For that reason, a search for new, more suitable biomarkers continues. Various studies suggested microRNAs as a potential solution, as they are involved in the pathogenesis of diabetic nephropathy, kidney cancer and kidney function impairment in general. Methods. Internet search engines were used to find and select relevant literature data and electronic databases. Results. Research published so far, in oncology especially, have reported various single microRNAs and panels of microRNAs as candidates for routine diagnostic implementation. Chronic kidney disease is, however, quite complex in terms of etiology of the disease occurrence, since there are many causes that can lead to kidney tissue damage and impairment of its function and finally full development of the chronic kidney disease. MicroRNAs are stable in bodily fluids, and hemodialysis procedure does not affect their levels. Also, high RNase activity in chronic kidney disease patients does not accelerate microRNA degradation in their samples. Conclusions. Literature data suggest that microRNAs are appropriate candidates for diagnostic use in chronic kidney disease. However, there are challenges that are yet to be overcome in order to use microRNAs routinely.","PeriodicalId":7132,"journal":{"name":"Acta Facultatis Medicae Naissensis","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Facultatis Medicae Naissensis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5937/afmnai40-39805","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction. Standard biomarkers for the diagnosis and follow-up of chronic kidney disease patients are appropriate neither in early diagnostics, adequate follow-up and progression assessment nor in complication development risk assessment. For that reason, a search for new, more suitable biomarkers continues. Various studies suggested microRNAs as a potential solution, as they are involved in the pathogenesis of diabetic nephropathy, kidney cancer and kidney function impairment in general. Methods. Internet search engines were used to find and select relevant literature data and electronic databases. Results. Research published so far, in oncology especially, have reported various single microRNAs and panels of microRNAs as candidates for routine diagnostic implementation. Chronic kidney disease is, however, quite complex in terms of etiology of the disease occurrence, since there are many causes that can lead to kidney tissue damage and impairment of its function and finally full development of the chronic kidney disease. MicroRNAs are stable in bodily fluids, and hemodialysis procedure does not affect their levels. Also, high RNase activity in chronic kidney disease patients does not accelerate microRNA degradation in their samples. Conclusions. Literature data suggest that microRNAs are appropriate candidates for diagnostic use in chronic kidney disease. However, there are challenges that are yet to be overcome in order to use microRNAs routinely.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
MicroRNA:慢性肾脏疾病的潜在生物标志物
介绍。慢性肾病患者诊断和随访的标准生物标志物既不适用于早期诊断、充分的随访和进展评估,也不适用于并发症发展风险评估。因此,寻找新的、更合适的生物标志物的工作仍在继续。各种研究表明,microRNAs是一种潜在的解决方案,因为它们通常与糖尿病肾病、肾癌和肾功能损害的发病机制有关。方法。利用网络搜索引擎查找和选择相关文献资料和电子数据库。结果。迄今为止发表的研究,特别是在肿瘤学方面,已经报道了各种单一microrna和microrna组作为常规诊断实施的候选物。然而,慢性肾脏疾病发生的病因是相当复杂的,因为有很多原因可以导致肾脏组织损伤和功能损害,最终导致慢性肾脏疾病的全面发展。微rna在体液中是稳定的,血液透析过程不会影响它们的水平。此外,慢性肾病患者的高RNase活性不会加速其样品中的microRNA降解。结论。文献资料表明,microrna是诊断慢性肾脏疾病的合适候选者。然而,为了常规使用microrna,还有一些挑战有待克服。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Acta Facultatis Medicae Naissensis
Acta Facultatis Medicae Naissensis MEDICINE, GENERAL & INTERNAL-
CiteScore
0.70
自引率
0.00%
发文量
13
审稿时长
12 weeks
期刊最新文献
Aesthetic appearance assessment in adolescents with idiopathic scoliosis A case of bizarre parosteal osteochondromatous proliferation (Nora's lesion): A brief description N-[2-(5-methoxy-1h-indole-3-yl)ethyl]acetamide may correct arterial hypertension in people with sleep problems Can continuous glucose monitoring be used as a new tool for diagnosing white coat hyperglycaemia and possibly some other entities? Overview of the possibility of bone replacement for the purpose of pre-prosthetic preparation of the patient
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1